India Branded Business Growth (Q4)
8%
+8pp YoY
India branded business grew 8% YoY in Q4, excluding discontinued trade generics.
JBCHEMICALSANDPHARMACEUT
Healthcare
01 May 2026
J B Chemicals and Pharmaceuticals Ltd — Q4 FY26
JB Chemicals reported a weak Q4 FY26 with revenue of ₹904 crore, down 5% YoY, as the quarter was an operational reset post Torrent Pharma's acquisition.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
JB Chemicals reported a weak Q4 FY26 with revenue of ₹904 crore, down 5% YoY, as the quarter was an operational reset post Torrent Pharma's acquisition. Adjusted EBITDA margin improved to 27% (up 200 bps YoY) driven by discontinuation of low-margin trade generics and distribution optimization. India branded business grew 8% (vs reported 2%), while international formulations declined due to container shipment disruptions. Management expects gradual normalization: India branded growth to return to low teens in a couple of quarters, international single-digit growth from Q2. CDMO business faces execution delays but has strong customer pipeline. Merger with Torrent expected to complete in 1-2 months. Key risk: West Asia shipping disruptions may persist, delaying international recovery.
Key Numbers
Chronic Business Growth (FY26)
19%
+5pp vs IPM
Chronic business grew 19% in FY26 vs industry growth of 14%.
Trade Generics Contribution to India Sales
7-8%
N/A
Trade generics contributed 7-8% of India sales before rationalization in Q4.
Field Force Strength
2,500
N/A
JB's India field force is around 2,500 MRs, unchanged from prior quarter.
Management Guidance
India branded business to return to low teens growth in a couple of quarters
Management expects India branded business to recover to double-digit/low-teens growth within 2 quarters.
Management guidance growthInternational business single-digit growth from Q2 FY27
International formulations expected to resume single-digit growth from Q2 FY27, assuming West Asia crisis eases.
Management guidance growthMerger completion in 1-2 months
Merger with Torrent Pharma expected to be effective within 1-2 months, with hearing in second week of June.
Management guidance otherCDMO business to return to positive growth on 12-month basis
CDMO business expected to grow on a 12-month basis, driven by new projects and contracts, but execution remains key.
Management guidance growthKey Risks
West Asia shipping disruptions
Container shipment constraints to West Asia and Asia impacted international business; Q1 remains uncertain.
high · management_commentaryCDMO execution delays
CDMO business faces delays in product development and delivery of new contracts, which could hinder growth.
medium · analyst_questionTrade generics rationalization drag on India growth
Discontinuation of trade generics (7-8% of India sales) will continue to suppress reported India growth for next 3 quarters.
medium · analyst_questionField force attrition and integration challenges
Higher attrition in JB's field force and potential rationalization may disrupt sales momentum.
medium · analyst_questionNotable Quotes
Q4 was a period of operational reset which temporarily impacted performance. However, we expect normalization beginning in Q1 and continuing going forward.
The trade generics business is not really a focus for us from here. We're looking at only growing the branded business more.
The good part is the customers are there. So JBI has all the top five customers and it has new contracts on hand. So the challenge is just the execution part.
Frequently Asked Questions
What was J B Chemicals's revenue in Q4 FY26?
J B Chemicals reported revenue of ₹904 Cr in Q4 FY26, representing a -5% change compared to the same quarter last year.
What guidance did J B Chemicals management give for FY27?
India branded business to return to low teens growth in a couple of quarters: Management expects India branded business to recover to double-digit/low-teens growth within 2 quarters. International business single-digit growth from Q2 FY27: International formulations expected to resume single-digit growth from Q2 FY27, assuming West Asia crisis eases. Merger completion in 1-2 months: Merger with Torrent Pharma expected to be effective within 1-2 months, with hearing in second week of June. CDMO business to return to positive growth on 12-month basis: CDMO business expected to grow on a 12-month basis, driven by new projects and contracts, but execution remains key.
What are the key risks for J B Chemicals in FY27?
Key risks include West Asia shipping disruptions — Container shipment constraints to West Asia and Asia impacted international business; Q1 remains uncertain.; CDMO execution delays — CDMO business faces delays in product development and delivery of new contracts, which could hinder growth.; Trade generics rationalization drag on India growth — Discontinuation of trade generics (7-8% of India sales) will continue to suppress reported India growth for next 3 quarters.; Field force attrition and integration challenges — Higher attrition in JB's field force and potential rationalization may disrupt sales momentum..
Did J B Chemicals meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full J B Chemicals Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.